SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fredun Pharmaceuticals informs about revised outcome of board meeting

03 May 2023 Evaluate
Fredun Pharmaceuticals has informed that Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on Preferential Basis to Non-Promoters on May 2, 2023. Further, the Warrant Holders have paid the balance of the consideration aggregating to Rs 2,38,34,085 and have applied for exercising their rights for conversion of 47,850 warrants into equivalent number of Equity Shares. Consequently, the Board of Directors in its meeting held today i.e., May 02, 2023 has allotted 47,850 Equity Shares of face value Rs 10 each to the warrant holders.

The above information is a part of company’s filings submitted to BSE.

Fredun Pharma Share Price

2043.90 -23.80 (-1.15%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×